{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T19:29:54Z","timestamp":1793734194563,"version":"4.6.1"},"reference-count":25,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","license":[{"start":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T00:00:00Z","timestamp":1777420800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.4103\/ijo.ijo_869_26","type":"journal-article","created":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T16:01:07Z","timestamp":1777478467000},"page":"630-632","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["From bench to bed: The evolution of anti-vascular endothelial growth factor therapies"],"prefix":"10.4103","volume":"74","author":[{"given":"Alok","family":"Sen","sequence":"first","affiliation":[{"name":"Department of Vitreo-Retina and Uvea, Sadguru Netra Chikitsalaya, Chitrakoot, Madhya Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaurav","family":"Kohli","sequence":"additional","affiliation":[{"name":"Department of Vitreo-Retina and Uvea, Sadguru Netra Chikitsalaya, Chitrakoot, Madhya Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aditi","family":"Agarwal","sequence":"additional","affiliation":[{"name":"Department of Vitreo-Retina and Uvea, Sadguru Netra Chikitsalaya, Chitrakoot, Madhya Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ritika","family":"Chauhan","sequence":"additional","affiliation":[{"name":"Department of Vitreo-Retina and Uvea, Sadguru Netra Chikitsalaya, Chitrakoot, Madhya Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,4,29]]},"reference":[{"key":"R1-20261103","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1126\/science.2479986","article-title":"Vascular endothelial growth factor is a secreted angiogenic mitogen","volume":"246","author":"Leung","year":"1989","journal-title":"Science"},{"key":"R2-20261103","doi-asserted-by":"crossref","first-page":"331","DOI":"10.3928\/1542-8877-20050701-14","article-title":"Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for neovascular age-related macular degeneration","volume":"36","author":"Rosenfeld","year":"2005","journal-title":"Ophthalmic Surg Lasers Imaging Off J Int Soc Imaging Eye"},{"key":"R3-20261103","doi-asserted-by":"crossref","first-page":"53","DOI":"10.2353\/ajpath.2007.061237","article-title":"Vascular endothelial growth factor-A is a survival factor for retinal neurons and a critical neuroprotectant during the adaptive response to ischemic injury","volume":"171","author":"Nishijima","year":"2007","journal-title":"Am J Pathol"},{"key":"R4-20261103","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.3390\/ph16081140","article-title":"Intravitreal anti-vascular endothelial growth factor therapies for retinal disorders","volume":"16","author":"Hang","year":"2023","journal-title":"Pharmaceuticals"},{"key":"R5-20261103","doi-asserted-by":"crossref","first-page":"xli","DOI":"10.1016\/j.ajo.2017.12.019","article-title":"Evolution of intravitreal therapy for retinal diseases-from CMV to CNV: The LXXIV Edward Jackson memorial lecture","volume":"191","author":"Martin","year":"2018","journal-title":"Am J Ophthalmol"},{"key":"R6-20261103","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s40123-021-00345-2","article-title":"Real-world safety outcomes of intravitreal ranibizumab biosimilar (razumab) therapy for chorioretinal diseases","volume":"10","author":"Chakraborty","year":"2021","journal-title":"Ophthalmol Ther"},{"key":"R7-20261103","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1056\/NEJMoa1102673","article-title":"Ranibizumab and bevacizumab for neovascular age-related macular degeneration","volume":"364","author":"Martin","year":"2011","journal-title":"N Engl J Med"},{"key":"R8-20261103","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.ophtha.2012.03.053","article-title":"Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results","volume":"119","author":"Martin","year":"2012","journal-title":"Ophthalmology"},{"key":"R9-20261103","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1016\/S0140-6736(13)61501-9","article-title":"Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial","volume":"382","author":"Chakravarthy","year":"2013","journal-title":"Lancet"},{"key":"R10-20261103","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1056\/NEJMoa054481","article-title":"Ranibizumab for neovascular age-related macular degeneration","volume":"355","author":"Rosenfeld","year":"2006","journal-title":"N Engl J Med"},{"key":"R11-20261103","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1056\/NEJMoa062655","article-title":"Ranibizumab versus verteporfin for neovascular age-related macular degeneration","volume":"355","author":"Brown","year":"2006","journal-title":"N Engl J Med"},{"key":"R12-20261103","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.ophtha.2011.12.039","article-title":"Ranibizumab for diabetic macular edema: Results from 2 phase III randomized trials: RISE and RIDE","volume":"119","author":"Nguyen","year":"2012","journal-title":"Ophthalmology"},{"key":"R13-20261103","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.ajo.2016.09.038","article-title":"Long-term outcomes of aflibercept treatment for neovascular age-related macular degeneration in a clinical setting","volume":"174","author":"Eleftheriadou","year":"2017","journal-title":"Am J Ophthalmol"},{"key":"R14-20261103","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.oret.2017.01.004","article-title":"Long-term safety and visual outcome of intravitreal aflibercept in neovascular age-related macular degeneration","volume":"1","author":"Kaiser","year":"2017","journal-title":"Ophthalmol Retina"},{"key":"R15-20261103","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1016\/j.ophtha.2016.02.022","article-title":"Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema: Two-year results from a comparative effectiveness randomized clinical trial","volume":"123","author":"Wells","year":"2016","journal-title":"Ophthalmology"},{"key":"R17-20261103","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.jcjo.2016.02.001","article-title":"Effect of aflibercept on refractory macular edema associated with central retinal vein occlusion","volume":"51","author":"Cohen","year":"2016","journal-title":"Can J Ophthalmol"},{"key":"R18-20261103","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1097\/IAE.0000000000004477","article-title":"Intravitreal aflibercept for macular edema due to central retinal vein occlusion: 5-year results of a Real-WORLD Study (INTRAMED-CRVO)","volume":"45","author":"Chatziralli","year":"2025","journal-title":"Retina"},{"key":"R19-20261103","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.2147\/OPTH.S185756","article-title":"Twelve-week dosing with Aflibercept in the treatment of neovascular age-related macular degeneration","volume":"13","author":"Garweg","year":"2019","journal-title":"Clin Ophthalmol"},{"key":"R20-20261103","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/S0140-6736(22)00018-6","article-title":"Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials","volume":"399","author":"Wykoff","year":"2022","journal-title":"Lancet"},{"key":"R21-20261103","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/j.ophtha.2024.02.014","article-title":"TENAYA and LUCERNE: Two-year results from the phase 3 neovascular age-related macular degeneration trials of faricimab with treat-and-extend dosing in year 2","volume":"131","author":"Khanani","year":"2024","journal-title":"Ophthalmology"},{"key":"R22-20261103","first-page":"e77906","article-title":"Efficacy and safety of high-dose intravitreal aflibercept in neovascular age-related macular degeneration (nAMD): A systematic review","volume":"17","author":"Evans","year":"2025","journal-title":"Cureus"},{"key":"R23-20261103","first-page":"24","article-title":"Real-life clinical effectiveness of Razumab\u00ae (the World\u2019s First Biosimilar of Ranibizumab) in retinal vein occlusion: A subgroup analysis of the pooled retrospective RE-ENACT study","volume":"241","author":"Sharma","year":"2019","journal-title":"Ophthalmol J Int Ophtalmol Int J Ophthalmol Z Augenheilkd"},{"key":"R24-20261103","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1007\/s40123-020-00277-3","article-title":"A multicenter, retrospective study (RE-ENACT 2) on RazumabTM (World\u2019s First Biosimilar Ranibizumab) in retinal vein occlusion","volume":"9","author":"Sharma","year":"2020","journal-title":"Ophthalmol Ther"},{"key":"R25-20261103","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1097\/IAE.0000000000001493","article-title":"Systemic pharmacokinetics and pharmacodynamics of intravitreal aflibercept, bevacizumab, and ranibizumab","volume":"37","author":"Avery","year":"2017","journal-title":"Retina"},{"key":"R26-20261103","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1016\/j.ophtha.2020.11.011","article-title":"Risk of inflammation, retinal vasculitis, and retinal occlusion\u2013related events with brolucizumab","volume":"128","author":"Mon\u00e9s","year":"2021","journal-title":"Ophthalmology"}],"container-title":["Indian Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/IJO.IJO_869_26","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T19:00:26Z","timestamp":1793732426000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/IJO.IJO_869_26"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,29]]},"references-count":25,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.4103\/ijo.ijo_869_26","relation":{},"ISSN":["0301-4738","1998-3689"],"issn-type":[{"value":"0301-4738","type":"print"},{"value":"1998-3689","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,29]]}}}